Cited by 25Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismNatural Products and Biological Research

Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens

Malina, Daniela M.T., Fonseca, Francisco A., Barbosa, Sílvio A., Kasmas, Soraia H., Machado, Valéria A., França, Carolina N., Borges, Ney C., Moreno, Ronilson A. +1 more·2015·Journal of clinical lipidology

Abstract

Objective Plant sterol (PS) supplementation has been widely used alone or combined with lipid-lowering therapies (LLTs) to reduce low-density lipoprotein (LDL) cholesterol. The effects of PS added to high-intensity LLT are less reported, especially regarding the effects on cholesterol synthesis and absorption.Methods A prospective, randomized, open-label study, with parallel arms and blinded end points was designed to evaluate the effects of addition of PS to LLT on LDL cholesterol, markers of cholesterol synthesis, and absorption. Eighty-six patients of both genders were submitted to a 4-wk run-in period with atorvastatin 10 mg (baseline). Following, subjects received atorvastatin 40 mg, ezetimibe 10 mg, or combination of both drugs for another 4-wk period (phase I). In phase II, capsules containing 2.0 g of PSs were added to previous assigned treatments for 4 wk. Lipids, apolipoproteins, plasma campesterol, β-sitosterol, and desmosterol levels were assayed at all time points. Within and between-group analyses were performed.Results Compared with baseline, atorvastatin 40 mg reduced total and LDL cholesterol (3% and 22%, respectively, P < .05), increased β-sitosterol, campesterol/cholesterol, and β-sitosterol/cholesterol ratios (39%, 47%, and 32%, respectively, P < .05); ezetimibe 10 mg reduced campesterol and campesterol/cholesterol ratio (67% and 70%, respectively, P < .05), and the combined therapy decreased total and LDL cholesterol (22% and 38%, respectively, P < .05), campesterol, β-sitosterol, and campesterol/cholesterol ratio (54%, 40%, and 27%, P < .05). Addition of PS further reduced total and LDL cholesterol by ∼ 7.7 and 6.5%, respectively, in the atorvastatin therapy group and 5.0 and 4.0% in the combined therapy group (P < .05, for all), with no further effects in absorption or synthesis markers.Conclusions PS added to LLT can further improve lipid profile, without additional effects on intestinal sterol absorption or synthesis.

Integrity signals

Registry

Crossref · 10.1016/j.jacl.2015.04.003

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nutraceuticals, either alone or in combination, when administered with statins seem to confer additional benefit on plasma lipid profiles, allowing statin doses to be reduced without diminishing total cholesterol and LDL-C reduction, and significantly limiting adverse effects.

    “Nutraceuticals, either alone or in combination, when administered with statins seem to confer additional benefit on plasma lipid profiles (Table 5), allowing the statin doses to be reduced (in case of statin intolerance) without diminishing the results in terms of total cholesterol (TC) and LDL-C reduction (109-121) and significantly limiting adverse effects (122).”

    From The Role of Nutraceuticals in Statin Intolerant Patients (2018) · cites this paper as [116]

Cites

Flagged first, then by citations

1 of the 45 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Malina, D. M. T., Fonseca, F. A., Barbosa, S. A., Kasmas, S. H., Machado, V. A., França, C. N., Borges, N. C., Moreno, R. A., & Izar, M. C.
Affiliations
  • Universidade Federal de São Paulo (BR)
  • Universidade de Santo Amaro (BR)
Corresponding author
Izar, Maria C.
Venue
Journal of clinical lipidology
Publisher
Elsevier BV
Published
2015-07
Volume
9
Issue
4
Pages
542-552
ISSN
  • 1876-4789 (ISSN-L)
  • 1933-2874
OpenAlex
W2131855630
Cited by
25
References
45
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 1 · 2015: 1
FWCI
3.02
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of clinical lipidology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Surgery › Natural Products and Biological Research
Keywords
phytosterols, lipid-lowering therapy, LDL cholesterol, atorvastatin, ezetimibe, combination therapy, cholesterol absorption, cholesterol biosynthesis, campesterol, β-sitosterol, desmosterol, apolipoproteins, hypercholesterolemia
MeSH terms
Atorvastatin, Ezetimibe, Aged, Anticholesteremic Agents, Apolipoproteins, Cholesterol, Drug Synergism, Female, Humans, Hypercholesterolemia, Lipids, Cholesterol, LDL, Male, Middle Aged, Phytosterols, Sitosterols, Dietary Supplements, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review